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Abstract:  Tissue  simulating  phantoms  are  an  important  part  of 
instrumentation validation, standardization/training and clinical translation. 
Properly  used,  phantoms  form  the  backbone  of  sound  quality  control 
procedures. We describe the development and testing of a series of optically 
turbid  phantoms  used  in  a  multi-center  American  College  of  Radiology 
Imaging Network (ACRIN) clinical trial of Diffuse Optical Spectroscopic 
Imaging (DOSI). The ACRIN trial is designed to measure the response of 
breast  tumors  to  neoadjuvant  chemotherapy.  Phantom  measurements  are 
used  to  determine  absolute  instrument  response  functions  during  each 
measurement  session  and  assess  both  long  and  short-term  operator  and 
instrument reliability. 
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1. Introduction: phantoms are important components of clinical translation 
1.1. Phantoms in the development of biomedical optics 
Tissue-simulating phantoms are an important part of technology development, validation and 
translation. From the early years of biomedical optics, phantoms have provided controls of 
“known” optical properties (i.e., absorption and scattering). In the near infrared (NIR) spectral 
region  (i.e.,  650-1000  nm)  phantoms  must  have  a  high  level  of  turbidity  to  simulate  the 
multiple scattering of NIR photons in biological tissues [1,2]. Phantoms can simulate tissue 
features  by  controlling  the  magnitude  and  spectral  dependence  of  their  optical  properties. 
While tissues are assumed to be “homogeneous,” more accurate geometries can be modeled. 
The states of absorbing molecules, such as hemoglobin [3,4] or water and lipids [5,6] can be 
modeled via phantoms. As optical imaging technologies move towards the clinic, groups have 
documented phantom use for training operators [7] and for comparing instrument performance 
across  different  imaging  platforms  [8].  Phantom  materials  and  fabrication  strategies  for 
biomedical optics have been summarized in a comprehensive review [9]. 
In Diffuse Optical Spectroscopic Imaging (DOSI), or any diffuse optical approach (e.g., 
diffuse optical tomography, DOT, diffuse optical spectroscopy, DOS), instrument calibration 
is  required.  Such  practices  are  nothing  new:  examples  include  reflectance  standards  for 
wavelength  calibration  or  scattering  solutions  for  phase  and  amplitude  calibration  in 
fluorescence lifetime measurements. For diffuse optical approaches, typically phantoms with 
“known” optical properties are used to remove unknown source and detector characteristics. 
The instrument response function (for time domain), phase offsets/amplitude scale factors (for 
frequency domain) or intensity variations (for multi-spatial domain) can all be assessed using 
tissue-simulating  phantoms.  However,  there  is  no  formal  consensus  for  this  calibration 
process; typically each instrument has its own calibration procedure and phantoms. 
1.2. Use of phantoms in ACRIN 6691 
Phantoms in the context of multicenter clinical trials are not only needed for calibration, but 
are  further  needed  to  ensure  that  instrument  performance  is  maintained  across  multiple 
research sites, each with different phantoms, instruments and operators. Performance must 
also  be  documented  over  extended  periods  of  time,  especially  in  the  case  of  longitudinal 
measurements on human subjects. For DOSI and related approaches, the robustness of the 
calibration  process  in  light  of  these  changing  experimental  conditions  has  not  been  well 
documented. The validity of any clinical trial depends upon instrument and operator precision, 
stability, and accuracy, all of which can be assessed using phantoms. 
DOSI  is  now  undergoing  standardization and  validation  on  neoadjuvant chemotherapy 
patients in an investigator-initiated, hypothesis-based multi-center clinical trial supported by 
the NIH and the American College of Radiology Imaging Network (ACRIN). ACRIN 6691 
employs identical, “frozen” DOSI technology at each site and was activated on April 1, 2011. 
Identical DOSI platforms have been placed at Dartmouth, the University of Pennsylvania, 
Massachusetts General Hospital, UC San Francisco, and UC Irvine. The goal of the study is to 
measure breast tumor response to neoadjuvant chemotherapy, and compare the velocity of the 
optically-measured tumor response to the surgically-determined tumor pathological state at 
the  conclusion  of  chemotherapy  [10].  One  of  the  aims  of  ACRIN  6691  is  to  establish 
procedures and methods for multi-center Quality Control and Instrumentation (QC/I). This 
aim  is  critical  because  DOSI  is  used  at  4  time  points  (pre-therapy,  1  week  after  starting 
therapy, midway through therapy and at the conclusion of therapy) that span several months. 
In  addition,  data  will  be  combined  from  5  DOSI  instruments,  using  at  least  5  different 
operators  with  5  sets  of  phantoms.  In  this  paper  we  document  our  phantom  construction 
methods and provide preliminary results on instrument calibration stability. 
#164538 - $15.00 USD Received 14 Mar 2012; accepted 27 Mar 2012; published 16 Apr 2012
(C) 2012 OSA 1 May 2012 / Vol. 3,  No. 5 / BIOMEDICAL OPTICS EXPRESS  9672. Phantoms used in the ACRIN 6691 study 
2.1. Diffuse Optical Spectroscopic Imaging technology 
The current clinical DOSI instrument employed in ACRIN 6691combines frequency-domain 
and  steady-state  spectroscopies  to  provide  quantitative  broadband  absorption  and  reduced 
scattering  spectra  from  650  to  1000  nm  using  a  single  source-detector  pair  [11].  The 
frequency-domain  portion  of  the  instrument  employs  multiple  amplitude-modulated  laser 
diodes at discrete wavelengths (660, 680, 785, 810, 830, and 850 nm). A network analyzer 
measures  the  phase  and  amplitude  of  the  detected  modulated  electronic  signal  from  an 
avalanche photodiode (APD) over a broad range of source modulation frequencies (401 points 
spanning  ~500MHz).  The  steady-state  portion  of  the  instrument  is  a  combination  of  a 
broadband lamp and spectrometer. A combined broadband measurement currently takes about 
5 seconds to complete. The entire system is cart-based. The only component in contact with 
the patient is a handheld probe which contains optical fibers and the APD inside a black 
plastic case. 
2.2. General overview of ACRIN 6691 phantom use 
Each ACRIN site is required to measure 2 different tissue-simulating phantoms per clinical 
measurement. One set of five identical phantoms (one for each ACRIN site) was constructed 
by  the  UC  Irvine  team  (a.k.a.  the  “ACRIN”  phantom  series).  The  other  set  of  identical 
phantoms  was  the  “biomimic”  soft  phantom  which  was  purchased  from  INO  (Quebec, 
Canada), a.k.a. the “INO” phantom series. We purchased 2 sets of 5 phantoms from INO; one 
set was distributed to the ACRIN sites (1 phantom per site) and the other set is a backup. Note 
that by working in a strongly diffuse regime at depth, scattering in our context is always 
meant to be the “reduced scattering” (i.e., scattering × (1 – g), where g is the anisotropy). 
The use of two phantoms offers both redundancy and validation insurance [12]. For the 
purposes of redundancy, either the ACRIN or INO phantom can be used as calibration for 
tissue measurements. Both phantoms have “similar” optical properties at the six laser diode 
wavelengths which require the calibration. For the purposes of validation, one phantom is 
used as the calibration for the other to test optical property recovery. Instrument performance 
and  operator  compliance  can  be  monitored  at  each  clinical  measurement  date.  The 
measurement protocol is built into the DOSI instrument control software. At the start of the 
clinical measurement, the operator measures both ACRIN and INO phantoms 3 times, each 
time  picking  up  and  re-placing  the  probe  onto  the  phantom.  These  values  are  averaged 
together  at  each  laser  diode  wavelength.  This  process  is  repeated  after  the  first  breast  is 
scanned and repeated again at the conclusion of the measurement. 
2.3. UC Irvine phantom construction method 
Solid phantoms made at the Beckman Laser Institute contain the following four components: 
P4 silicone rubber base and p4 silicone activator (Eager Polymers, Chicago, IL), along with 
anatase titanium(IV) oxide and water-soluble nigrosin ink (Sigma-Aldrich, St. Louis, MO) for 
scattering and absorption features. Components were mixed together in a specific manner to 
achieve optimal homogeneity. First, 3.5 g of titanium(IV) oxide was stirred into 300 g of the 
silicone activator by hand. Next, the mixture was placed in a Branson 1200 ultrasonic cleaner 
(Branson Ultrasonics, Danbury, CT) for 3 hours to break apart coagulated titanium(IV) oxide 
particles. In a separate container, 5 mL of nigrosin solution (1.5 g/1 Liter H2O) was added to a 
3000 g of the silicone base and mixed with a plunge mixer (Freeman Manufacturing & Supply 
Company, Avon, OH) for 5 minutes at 2000-2500 rpm. The titanium(IV) oxide suspension 
was then mixed into the nigrosin and silicone base mixture. The full set of components was 
mixed for 2 additional minutes with the plunge mixer and immediately placed into a Gas Vac 
II  industrial  vacuum  degassing  unit  (Freeman  Manufacturing  &  Supply  Company,  Avon, 
OH). The phantom mixture sat in the degassing chamber for approximately 2 minutes until a 
pressure of −29 mmHg was achieved. When the pressure reached −29 mmHg, bubbles began 
to collapse and the mixture was returned to normal atmospheric pressure. The mixture was 
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degassing unit for further degassing. After a pressure of −29 mmHg was reached, the chamber 
was vented, the containers were removed and placed on a flat surface, and phantoms were 
allowed to cure for 24 hours. 
2.4. Commercial phantoms 
Phantoms purchased from INO were specified to have absorption and reduced scattering in 
the range of 0.01 mm
−1and 1 mm
−1. The phantoms were prepared from a soft polyurethane 
matrix. Titanium dioxide particles (mean particle size 3 µm) were added as a scattering agent. 
A NIR dye was added to obtain an absorption feature at 750 nm. Carbon black was further 
added to raise the absorption at other wavelengths. INO made the phantom dimensions the 
same as the “ACRIN” phantoms using a mold supplied by the UC Irvine team (Fig. 1). 
 
Fig. 1. Setup for calibration measurement. In order to measure the same phantom volume each 
time, a mask was prepared to fit the phantom (left) and lock the probe in place (right). 
3. Phantom optical property measurement 
Standard DOSI  measurements of all phantoms  were initially performed at UC Irvine and 
subsequently  at  each  study  site  with  the  local  DOSI  instrumentation.  All  initial  phantom 
measurements were performed using another calibration phantom developed at UC Irvine that 
has been extensively characterized using a multi-distance and multi-frequency measurement 
protocol [13].  We  note  that  each  set  of  “ACRIN”  and  “INO”  phantoms  displayed  nearly 
identical optical properties within their class (<2% variation) using this method. 
The DOSI handheld probe at each study site has a “jig” that locks the source and detector 
separation at either 22, 28 or 34 mm (Fig. 1). All clinical measurements were performed at 28 
mm, whereas calibration was performed at 22 mm. The jig ensures consistent contact between 
the probe and the phantom surface and simplifies the measurement process. The molded case 
and probe mask surrounding the phantom ensures that the same region of the phantom is 
measured  each  time.  All  operators  were  trained  by  the  UC  Irvine  team  to  teach  proper 
measurement technique (see http://acrin.bli.uci.edu/ for training manuals and videos). 
4. Measurements of phantoms in the multi-center environment 
4.1. Diffuse Optical Spectroscopic Imaging stability assessed by phantom measurement 
Figure 2 provides stability measurements for each DOSI instrument measured over a one hour 
timeframe. The one hour timeframe is the typical patient measurement time in the study. For 
this “drift test” the probe is fixed onto a phantom for the measurement. The percent deviation 
of  the  optical  properties  from  their  mean  values  at  each  laser  diode  wavelength  is  then 
calculated. The laser diode wavelengths are slightly different (several nm) for each DOSI 
system; hence we averaged the optical property values at similar wavelengths because the 
phantom optical properties are not sharply-varying at these wavelengths. The data confirms 
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changed  ~0.4%  and  average  reduced  scattering  changed  ~0.2%  for  all  sites.  Using  this 
protocol method we detected a problem with 2 laser diodes which were subsequently repaired. 
 
Fig. 2. Drift tests for all DOSI instruments in ACRIN 6691. The percent change in optical 
properties for each laser diode measured over a 1 hour timeframe is presented for absorption 
(left) and reduced scattering (right). 
4.2. Phantom measurements performed during clinical measurements 
Figure 3 provides a summary of 180 different phantom measurements performed during an 8 
month  period  in  the  ACRIN  6691  study.  The  “INO”  class  of  phantoms  was  used  as  the 
calibration and the “ACRIN” class of phantom was used as the “tissue.” The results come 
from  2  measurement  sites  (UC  Irvine  and  Dartmouth)  with  the  majority  of  patient 
measurements  to  date.  The  calculated  variance  is  the  standard  deviation  of  this  sample 
population. Only laser diode data is shown because this is the data used for the calibration of 
the  frequency-domain  portion  of  the  DOSI  instrument,  which  is  the  most  critical  step. 
Broadband optical property values will be reported in a subsequent manuscript. 
 
Fig.  3.  Measured  differences  of  180  different  phantom  measurements  at  UC  Irvine  and 
Dartmouth. Overall the differences in absorption were on average~3.3% and the differences in 
reduced scattering were on average ~2.4%. 
The results of Fig. 3 reveal that DOSI instrument performance, as assessed by inter-site 
and inter-operator variability in a phantom measurement task over an 8 month period, is <5%. 
The average variation across all phantom measurements in absorption is 3.3% (max 4.7% @ 
850 nm) and the average variation in the reduced scattering is 2.4% (max 3.1% @ 690 nm). A 
small percentage (%7.7) of measurements were not included in the analysis; these data were 
#164538 - $15.00 USD Received 14 Mar 2012; accepted 27 Mar 2012; published 16 Apr 2012
(C) 2012 OSA 1 May 2012 / Vol. 3,  No. 5 / BIOMEDICAL OPTICS EXPRESS  970rejected for not passing our S/N criterion for acceptability. In these cases the fits of real and 
imaginary components (i.e., phase and amplitude) versus modulation frequency were poor. 
More will be described about this quality control filter in a subsequent manuscript. 
5. Discussion 
While there are diverse choices for phantoms (matrix, absorbing and scattering agents) [9] 
several criteria are essential for streamlining clinical translation in a multi-center environment. 
We require phantoms that are stable over a defined period of time (e.g., the length of the trial). 
Phantoms must be simple to use and cannot rely upon chemical mixtures that are prepared for 
each  clinical  measurement.  Phantoms  should  represent  reasonable  approximations  to  the 
absorption and scattering properties of breast tissues [11]. Although it would be advantageous 
to have similar tissue and phantom spectral shapes, this has not yet been realized in a manner 
suitable to the multi-center clinical environment. Thus, our phantoms do not take into account 
precise anatomical/spectral characteristics of real breast tissues, but instead represent bulk 
averages of their optical properties. In addition, our phantoms are also relatively large in size 
(~1  L  volume)  because  our  interest  is  breast  imaging,  and  thus  precise  concentrations  of 
microspheres to accurately model tissue scattering is impractical. 
Our primary concern is measurement repeatability, not exact tissue feature replication. 
Data  presented  here  strongly  suggests  that  the  frequency-domain  calibration  procedure 
employed  for  DOSI  in  ACRIN  6691  is  precise  enough  for  the  multi-center  environment. 
Given that these measurements were taken over the course of several months, this enhances 
our confidence that longitudinal multi-center measurements are possible for DOSI. There are 
still challenges to navigate, as evidenced by the rejection of some of the data points in our 
analysis. We are investigating the origins of these errors and pursuing strategies to distinguish 
between instrument vs. operator error during each measurement session. One way to assess 
this is by stability testing (e.g., Fig. 2). Our preliminary results show that there is less than 2% 
variation in absorption and <0.5% in scattering for 1 hour acquisitions. This suggests that 
using proper QC/I methods, operator error can be identified and reduced. 
6. Conclusion 
While this use of tissue-simulating phantoms cannot safeguard against all possible problems, 
proper phantom use for quality control is essential for multi-center studies. In this pilot study 
we have demonstrated that the frequency-domain calibration process for DOSI is stable, with 
less than 5% variance over the course of several instruments, operators, phantoms, and time 
points (~8 months). Importantly, tissue simulating phantoms allow us to reliably compare 
DOSI patient results during longitudinal studies across multiple sites. 
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